Clinical Trials Search
Clinical Trial 18786
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT03071406
Phase: Phase II
Prinicipal Investigator: Sungjune Kim
Study Title
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Summary
The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will stimulate the body's immune system to work against tumor cells. This study will test an investigational use of nivolumab.
Objective
Primary: To compare the efficacy, as measured by objective response rate (ORR), provided by nivolumab plus ipilimumab with or without SBRT in subjects with metastatic Merkel cell carcinoma. Secondary: To compare the progression free survival (PFS) of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To compare the overall survival (OS) of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To evaluate the local control of irradiated tumor provided by SBRT in combination with nivolumab and ipilimumab. To assess the overall safety and tolerability of of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To evaluate whether PD-L1 expression is a predictive biomarker for ORR. To evaluate the Health Related Quality of Life (HRQoL) as assessed by European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.
Therapies
Medications
BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.